Latest News Releases

PTA-Adhoc: Biofrontera AG: Biofrontera Inc. announces USD15 million private placement

Public disclosure of inside information according to article 17 MAR

Leverkusen (pta038/29.11.2021/16:20) - Biofrontera AG announces that its US subsidiary Biofrontera Inc. has entered into a private placement in the amount of USD 15 million (gross proceeds).
Biofrontera Inc. will issue 2,875,143 common shares (Nasdaq: BFRI) and warrants to an institutional investor. The combined purchase price for one common share (or common share equivalent) with warrant is USD 5.25, priced at-the-market under Nasdaq rules. The warrants have an exercise price of USD5.25 per share, will be immediately exercisable, and will expire five years from the issuance date.
The private placement is expected to close on or about December 1, 2021, subject to the satisfaction of customary closing conditions.
Following a successful private placement, Biofrontera AG will hold approximately 52% shares in Biofrontera Inc.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate
other stock exchanges: Nasdaq

[ source: http://www.pressetext.com/news/20211129038 ]

Biofrontera AG – an attractive investment

We are experts in photodynamic therapy. With our innovative products and treatment methods, we make our contribution to skin health and at the same time create value for our investors.

Biofrontera is listed on the Frankfurt Stock Exchange (B8F) and on the NASDAQ Stock Exchange (BFRA) in New York.